LDX Lumos Diagnostics Holdings Limited
Healthcare · Medical Devices
· website
$0.10
52wk 0.08 – 0.33
Overall
—
Value
—
Growth
—
Health
—
Quality
—
Momentum
—
Dividend
—
Price
About Lumos Diagnostics Holdings Limited
Lumos Diagnostics Holdings Limited develops, manufactures, and commercializes point-of-care diagnostic products for diagnosis and management of infectious diseases in the United States. The company's products include FebriDx, a point-of-care diagnostic test for detecting and differentiating viral and bacterial respiratory infections; and ViraDx, a three-in-one point-of-care test for influenza A, influenza B, and COVID-19. It also provides assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos Diagnostics Holdings Limited was incorporated in 2018 and is based in Carlsbad, California.
Fundamental trends
Financial statements
Loading…
Key metrics
Market cap
$99.21M
P/E (trailing)
—
P/E (forward)
-7.42
EPS (trailing)
-0.02
Dividend yield
—
Payout ratio
0.0%
Beta
0.54
EV / EBITDA
-7.77
Price / Book
10.50
ROE
-123.3%
Operating margin
-106.4%
Net margin
-75.8%
Total cash
$2.99M
Total debt
$6.47M
Current ratio
0.73
Debt / Equity
1.24
Free cash flow
$-2.46M
Avg volume
3.51M
Latest annual results
(FY ending 30 Jun 2025)
- Revenue$12.50M
- Gross profit$7.91M
- Operating income-$7.84M
- Net income-$7.18M
- Diluted EPS-0.01
- Free cash flow-$9.39M
- Net debt$5.03M